-
1.发明授权Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases 有权用于肥胖症，糖尿病，代谢综合征，神经变性疾病和线粒体功能障碍相关的疾病有关的治疗或预防疾病的药物组合物
公开(公告)号：EP1848432B1
公开(公告)日：2013-07-17
申请号：EP06715982.2
申请日：2006-02-15
发明人： YOO, Sang-Ku , PARK, Myunggyu , JO, In Geun , KWAK, Taehwan
IPC分类号： A61P3/04 , A61P3/10 , A61P3/00 , A61P1/16 , A61P9/10 , A61P29/00 , A61P27/02 , A61P9/12 , A61K31/352 , A61K31/353 , A61K31/343
CPC分类号： A61K31/352 , A61K8/498 , A61K9/0014 , A61K9/06 , A61K9/146 , A61K9/2054 , A61K31/343 , A61K31/353 , A61K31/453 , A61Q19/00
摘要： Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
-
2.发明公开OBESITY AND METABOLIC SYNDROME TREATMENT WITH TANSHINONE DERIVATIVES WHICH INCREASE METABOLIC ACTIVITY 审中-公开肥胖和代谢综合征TRANSHINON衍生物用于提高代谢活力的治疗
公开(公告)号：EP1706108A1
公开(公告)日：2006-10-04
申请号：EP04808674.8
申请日：2004-12-30
发明人： KWAK, Taehwan , PARK, Myunggyu
IPC分类号： A61K31/343 , A61K36/18 , A61P3/04
CPC分类号： A61Q19/06 , A23C9/152 , A23L2/02 , A23L2/52 , A23L33/105 , A23V2002/00 , A61K8/4973 , A61K9/0095 , A61K9/2054 , A61K31/343 , A61K36/537 , A61K2300/00 , A23V2250/0606 , A23V2250/032 , A23V2250/704 , A23V2200/332 , A23V2200/328 , A23V2200/326 , A23V2250/708 , A23V2250/606 , A23V2250/5042
摘要： The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.
-
3.发明公开
公开(公告)号：EP1994168A1
公开(公告)日：2008-11-26
申请号：EP07708979.5
申请日：2007-02-15
发明人： PARK, Myung-Gyu , YOO, Sang-Ku , JO, In Geun , KWAK, Taehwan
IPC分类号： C12Q1/26
CPC分类号： C12Q1/26 , A61K31/12 , A61K31/343 , A61K38/44 , C12Y106/05002
摘要： Provided is a method capable of effectively treating various diseases associated with energy excess, such as obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, via elevation of an NAD(P)+ZNAD(P)H ratio by increasing an NAD(P)+ concentration in vivo or in vitro through use of NAD(P)H as a substrate or coenzyme by oxidoreductase such as NAD(P)H:quinone oxidoreductase (NQO1), a method of screening a drug for the same and a therapeutic drug.
-
4.发明公开COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME 审中-公开连接用于治疗或预防疾病的预防前列腺和含有药物组合物结肠供应系统
公开(公告)号：EP2101757A1
公开(公告)日：2009-09-23
申请号：EP07834307.6
申请日：2007-11-26
申请人： Mazence Inc. , KT & G Co., Ltd.
发明人： KWAK, Taehwan , YOO, Sang-Ku , PARK, Myung-gyu
IPC分类号： A61K31/352 , A61P13/00
摘要： Provided is a naphthoquinone-based compound represented by Formula 1 or 2 having therapeutic effect on the treatment and/or prevention of prostate and/or testicle (seminal glands)-related diseases, and to a pharmaceutical composition of intestinal delivery system containing the same.
-
5.发明公开PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE 审中-公开药物组合物治疗和疾病的预防阳痿相关的GO
公开(公告)号：EP2099449A1
公开(公告)日：2009-09-16
申请号：EP07834308.4
申请日：2007-11-26
申请人： Mazence Inc. , KT & G Co., Ltd.
发明人： KWAK, Taehwan , YOO, Sang-Ku , PARK, Myung-gyu
IPC分类号： A61K31/352
摘要： Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
-
6.发明公开PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND 审中-公开药物组合物微粉化粒子的连接，以萘BASIS
公开(公告)号：EP2217225A2
公开(公告)日：2010-08-18
申请号：EP08837381.6
申请日：2008-10-07
申请人： Mazence Inc. , KT & G Co., Ltd.
发明人： JO, In Geun , YOO, Sang-Ku , PARK, Myung-Gyu , KWAK, Taehwan
IPC分类号： A61K31/122 , A61K31/352 , A61K31/34
CPC分类号： A61K31/122 , A61K9/14 , A61K9/143 , A61K9/145 , A61K9/5026 , A61K9/5042
摘要： Provided is a pharmaceutical composition having excellent in vivo absorption properties by increasing solubility and absorption rate of a sparingly-soluble naphthoquinone-based compound via incorporation of micronized particles of a certain naphthoquinone-based compound.
-
7.发明公开NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME 有权基于菲和药物组合物新的连接，以用于治疗或 预防与关联STOFFWECHSELSYSNDROM疾病的
公开(公告)号：EP2137175A1
公开(公告)日：2009-12-30
申请号：EP08741558.4
申请日：2008-04-25
申请人： Mazence Inc. , KT & G Co., Ltd.
发明人： YOO, Sang-Ku , KANG, Ku Suk , YOO, Sang Woo , KWAK, Taehwan
IPC分类号： C07D307/77
CPC分类号： C07D307/77 , C07D311/78
摘要： Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving metabolic syndromes, comprising (a) a therapeutically effective amount of a particular compound represented by Formula 1 as defined in the specification, or isomer, prodrug, or solvate or thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
-
8.发明公开
公开(公告)号：EP2094262A1
公开(公告)日：2009-09-02
申请号：EP07834305.0
申请日：2007-11-26
申请人： Mazence Inc. , KT & G Co., Ltd.
发明人： JO, In Geun , YOO, Sang-Ku , PARK, Myung-gyu , KWAK, Taehwan
IPC分类号： A61K31/343 , A61K31/453 , A61K9/32 , A61P3/10 , A61P3/04
摘要： Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a particular phenanthrenequinone-based compound, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient.
-
9.发明授权NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME 有权基于菲和药物组合物新的连接，以用于治疗或 预防与关联STOFFWECHSELSYSNDROM疾病的
公开(公告)号：EP2137175B1
公开(公告)日：2013-09-25
申请号：EP08741558.4
申请日：2008-04-25
申请人： Mazence Inc. , KT & G Co., Ltd.
发明人： YOO, Sang-Ku , KANG, Ku Suk , YOO, Sang Woo , KWAK, Taehwan
IPC分类号： C07D307/77 , A61K31/343 , A61P3/00
CPC分类号： C07D307/77 , C07D311/78
-
公开(公告)号：EP2099448A1
公开(公告)日：2009-09-16
申请号：EP07834306.8
申请日：2007-11-26
申请人： Mazence Inc. , KT & G Co., Ltd.
发明人： KWAK, Taehwan , YOO, Sang-Ku , PARK, Myung-gyu
摘要： Provided is a pharmaceutical composition for the treatment and/or prevention of restenosis including (a) a therapeutically effective amount of a particular compound represented by Formula 1 and 2, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.016 秒)
